Engineered moths could replace mice in studies on antimicrobial resistance

A scientific breakthrough not only promises faster testing for antimicrobial resistance, but also an ethical solution to the ...

Gene-editing therapy removes extra chromosome behind Down syndrome in a landmark lab study

Scientists have achieved a genetic feat once thought impossible: removing an entire extra human chromosome using gene-editing ...
AlphaGalileo

Nanoparticle-Mediated Photodynamic Therapy Takes on Triple-negative Breast Cancer

Researchers have developed a new biomimetic nanocomposite (mPDA-Cas9) for treating triple-negative breast cancer (TNBC) by combining CRISPR/Cas9 gene ...

CRISPR approach turns oncogene amplification into a weakness in multiple solid tumors

The onset and aggressiveness of cancer are related to the abnormal behavior of certain genes, known as oncogenes. The best-known of these alterations is mutation, but it is not the only one. Sometimes ...

Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline

CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an ...
The Pharma Letter

Intellia Therapeutics

A U.S. clinical-stage genome editing company headquartered in Cambridge, Massachusetts. The company runs global clinical ...
Chemistry World

In 2023, the UK was the first country to approve a Crispr therapy. How’s it doing?

In November 2023, the UK became the first country in the world to authorise a Crispr gene-editing therapy.

Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies

Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development, describing the application of optical genome mapping (OGM) to ...
EurekAlert!

A new experimental strategy uses gene editing against tumours with too many oncogenes

In cellular and animal models of neuroblastoma, small cell lung cancer and colon cancer, this strategy reduces tumours, ...

Assessing CRISPR Therapeutics’ Valuation As Recent Trading Puts CRSP Back In Focus

Why CRISPR Therapeutics Is On Investors’ Radar Today CRISPR Therapeutics (CRSP) has attracted fresh attention after recent trading left the stock around $54.65, with performance mixed over the past ...